![]() ![]() Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. This MOA could possibly explain the potent, broad-spectrum activity we observe with pravibismane in MIC studies with patient clinical isolates compared to other antibiotics." "These new data corroborate findings from our earlier pravibismane MOA studies that also suggested disruption of bacterial membrane bioenergetics. Jeff Millard, Chief Scientific Officer of Microbion Corp. "We are excited to present pravibismane's mechanism of action at the genetic level by using the elegant CRISPER-Cas9 engineered E. These findings suggest that the reduction of phospholipids and fatty acid biosynthesis disrupts bacterial membrane architecture and the ability of the electron transport chain to embed proteins in the membrane.Pravibismane impacts cellular bioenergetics by potentially reducing the number of protons synthesized and ultimately the levels of adenosine triphosphate (ATP) produced.coli strains that had engineered knockdown of genes involved in energy production, fatty acid biosynthesis and cellular envelop biosynthesis were more sensitive to pravibismane than control strains. Over 170 CRISPR (clustered regularly interspaced short palindromic repeats)-Cas engineered essential gene knockdown strains of E.Session Title: AAR08 New Antimicrobial Agents: New Small Molecules? Non-Beta-Lactamase Inhibitors (BLIs) ![]() CDT / Exhibit Poster Hall (Hall BCD) AAR-SUNDAY-493 Title: Pravibismane Impacts Bacterial Bioenergetics and Fatty Acid BiosynthesisÄate/Time/Board Location: J/ 10:00 a.m. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |